ACTIVE SURVEILLANCE FOR PROSTATE CANCER
|
|
- Wesley Dean
- 6 years ago
- Views:
Transcription
1 ACTIVE SURVEILLANCE FOR PROSTATE CANCER Dr. Michael J Metcalfe PGY-2 Department of Urological Sciences April 25, 2012 CASE RM 65 year old active Caucasian male, married. PSA= 7.0 T2a Gleason 3+3=6 2/6 cores positive 2mm total core involvement No LVI IPSS= 7 (1) SHIM = 29 Hx: Left Knee Surgery, Asthma Med s: Symbicort Father died at 86, Cardiovascular causes. 1
2 CASE RM Treatment Options Low Risk Prostate Cancer AUA 2007, NCCN 2012, EAU 2007 Guidelines: Radical prostatectomy External Beam Radiation Therapy Brachytherapy Active surveillance CASE RM Treatment Options Low Risk Prostate Cancer AUA 2007, NCCN 2012, EAU 2007 Guidelines: Radical prostatectomy External Beam Radiation Therapy Brachytherapy ACTIVE SURVEILLANCE (Treatment of choice, NICE 2011) 2
3 Date Stage PSA Path Grade Positive cores Size* Feb. '07 ct2a core 3+3=6 2/6 2mm May ' core 3+3=6 2/12 4mm Dec. ' Jan. ' Apr. ' Dec. ' core 3+4=7 2/10 2mm Apr. ' June '09 pt2a Rpx 4+4=8 1 cm nodule -ve SV, -Margins June 09- Apr. 2012: PSA < 0.02 Prostate Volume= 35 cc on TRUS *Size=Total Core Involvement OBJECTIVES Review current use and acceptance of AS in low risk prostate cancer. Review appropriate patients for AS Review markers for disease progression for patients on AS. Review safety of AS based on PIII trials and registration trials. Review benefit of secondary chemoprevention in patients on surveillance. 3
4 WHAT IS ACTIVE SURVEILLANCE? NOT active surveillance of prostate cancer as defined in the pre PSA era. Involved waiting until clinical progression the palliation NOT watchful waiting Reserved for patients who are not candidates for radical therapy on the basis of life expectancy and aims to delay treatment until palliation. IS an ACTIVE decision to monitor a patient with prostate cancer who has a low risk of progressing and there is intent to curatively treat the cancer if it progresses. 4
5 RISK OF PROSTATE CANCER MORTALITY FROM MODERATELY DIFFERENTIATED PROSTATE CA Albertson PC, JAMA 2009, 293, T- STAGE SHIFTS IN BC SINCE PSA TESTING 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% T4 T3 T2 T PSA TESTING INITIATED BCCA referred patients only 5
6 STAGE SHIFT IN BC: PROPORTION OF PATIENTS REFERRED TO BCCA WITH N+ OR M+ DISEASE PSA TESTING SCREENING FOR PROSTATE CANCER- ERSPC AT 11 YEARS FOLLOW UP NNTS= 1055 NNT= 37 6
7 SCREENING IN PROSTATE CANCER PLCO (USA) 40 % reduction in mortality reduction. ERSPC (EUROPE) 20% mortality reduction 25% reduction in metastatic disease 50% more cancers found NNTS-1410 NNTT-48 US PREVENTATIVE TASK FORCE Recommends against screening for Prostate cancer. PREVALENCE OF AS AT MSK FROM Cancer Volume 117, Issue 21, pages , 11 APR 2011 DOI: /cncr
8 LONGEVITY QUALITY OF LIFE A FINE BALANCE HOW MANY PEOPLE ARE CHOOSING AS? In a large series of almost 800 US men, from 7 centers 40% chose surgery, 31% conformal beam radiotherapy, 21% chose brachytherapy 8% chose AS. Anandas CN, et al. BJU International, 2010 Of 1,886 men with all 5 criteria documented: 16.4% (310 of 1,886) met all 5 surveillance criteria and 9.0% (28 of 310) chose surveillance. Older age was the only demographic predictor of surveillance. Barocas, D. A. et al. J. Urol. 180,(2008) 8
9 HOW MANY ARE ON ACTIVE SURVEILLANCE LOW RISK HIGH RISK RESULTS FROM CAPSURE DATABASE Cooperberg, JCO 2010 REASONS BEHIND TREATMENT CHOICE Reasons for AS: 1. Unknown 2. Other- didn t want active or invasive treatment. 3. More Convenient 4. Fear of Side Effects 5. Fear of Other Options BJU International NOV
10 BARRIERS TO ACTIVE SURVEILLANCE Predicting clinically insignificant Prostate Cancer Lack of defined optimal monitoring patients on Active Surveillance Potential need for multiple Prostate Biopsies Effect on Delayed Therapy Secondary preventative measures QOL on Active Surveillance PREDICTING CLINICALLY INSIGNIFICANT PROSTATE CA: Risk Stratification: PSA (Absolute, velocity, density ) Gleason Grade ct stage Volume of Disease PCA 3 MRI 10
11 CURRENT PUBLISHED ACTIVE SURVEILLANCE PROTOCOLS Clinical Stage PSA (ng/ml) Gleason Score on Biopsy PSA Density Number of pos. Cores U of T EPSTEIN* PRIAS UCSF CANARY BCCA T1c T1c T1c or T2 T1 or T2 ct1-t2 < T2b <10 N/A < 10 <10 - < 10 <3+3=6 <3+3=6 <3+3=6 < 3+3=6 - < 3+3=6 - < 0.15 < <2 2 of (8-12) < 33% min. 10 core - No level 1 evidence to support any surveillance protocol * Epstein- Very low risk criteria PSA IS A USEFUL PREDICTOR OF INSIGNIFICANT PROSTATE CANCER A Single entry PSA is a useful predictor of Clinically Insignificant Disease Elevated PSA at or before 50 is a risk factor for advanced prostate cancer Scardino, BMC Med 2008 PSA at baseline > 10 is a useful predictor of patients on AS who undergo definitive intervention. Klotz, JCO 2011 PSA and PSA Density at Diagnosis is a significant predictor of future intervention in patients on Active Surveillance. Tosoian, JCO 2011 PSA < 10 is an independent predictor of no overall benefit in 10 year survival with RP. PiVOT,
12 PIVOT TRIAL- OBSERVATION VS RP 731 men randomized to: Observation (n= 367) RP (n-364) Mean age of 66.8 Median 10 years follow No difference in Prostate Cancer Mortality between radical treatment and observation for: PSA < 10 D Amico Low Risk (Intention to treat analysis) Wilt, GU ASCO
13 612 patients who had RP in Germany met A.S. protocols. 2 Groups: AS-A- < T2a, < Gleason 7, PSA < 10 AS-B < T2a, < Gleason 7, PSA < 15 >25% of patients had pathological upgrading in their RP Specimen, independent of which group. Addressed by 12-core re-biopsy which demonstrated upgrade in 17% of biopsies PCA - 3 AS A MARKER FOR PROGRESSION PCA 3 has a direct correlation with: Tumour volume, Margins at time of RP and positive biopsy percentage. Durand, BJUI 2012 Can discriminate between low volume / low grade cancers. Nakanashi, J Urol 2008 PCA3 > 25 associated with Significant disease (OR 12.74, P=0.003) in 106 men. Ploussard et al, Eur Urol 2011 PCA3 score predicts extracapsular extension and tumor volume. Whiman et al, J Urol
14 PCA 3 IN PREDICTING ADVERSE PATHOLOGY Haese et al, Eur Urol 2011 ROLE OF MRI New techniques improve incremental diagnostic accuracy and improves assessment of disease volume. Klowkowicz et al 2010 Endorectal coil prostate MRI added to Epstein criteria in the ability to predict low risk disease prior to radical prostatectomy. Margolis, J Clin Oncol 2012 PRIAS found that T2 DW and DCE MRI found more aggressive disease in 27% of patients in their active surveillance group. Somford, GU ASCO patients with a lesion suggestive of malignancy on MRI had an increased risk of gleason score upgrading on subsequent biopsy. Fradet, Radiology
15 SUMMARY: ELIGIBILITY FOR ACTIVE SURVEILLANCE No eligibility criteria has been identified as being optimal for Active Surveillance. It is a spectrum of disease and stratification must take this continuum into consideration. PSA < 10 and prostate biopsy with D Amico risk cliassification are reliable predictor at 10 years for clinically insignificant disease. If Biopsy is performed, a confirmation biopsy is recommended. PCA3 and MRI are appearing to provide additive information to risk stratification of Prostate Cancer and may be used in nomograms/ risk criteria in future. Patient factors are equally important as prostate cancer factors. SURVEILLANCE PROTOCOLS PSA University of Toronto John's Hopkins PRIAS UCSF CANARY / UBC 3 monthly for 2 years; 6 monthly 6 monthly 3 monthly 3 monthly 3 monthly PSA DRE 6 monthly DRE 6 monthly 6 monthly 3 monthly 6 monthly DRE Re-biopsy Indica9on for re- biopsy 6-12 months in the first year, then q 3-4 Annually 1,2 and 7 years, PSA DT < 3 year None, no PSA kine9cs ct3, PSADT< 10 years TRUS- q 6-12 mo. Bx years PSA DT< 3 years 0, 6-12 months, q2 years. Physician Discretion PSA DT< 3 years 15
16 REASONS FOR LEAVING ACTIVE SURVEILLANCE A multiinstitutional cohort of 262 men from 4 institutions < 75 years old with: PSA< 10, ct1-t2a, Gleason < 6, < 3 + cores. Repeat Biopsy at diagnosis, T=0 at rebiopsy date. Surveillance: DRE and PSA q 6-12 months Biopsy before 18 months then q 1-3 years or for cause MRI intermittent, q 1-3 years, concerning features= Bx Median Follow up= 29 months 43 patients received Treatment: 2 year probability of being on AS= 91% 5 year probability of being on AS= 75% PREDICTORS OF DISCONTINUING AS Eggener, J of Urol
17 TORONTO- ACTIVE SURVEILLANCE EXPERIENCE 450 patients, Median age years Median Follow up Inclusion for < 70 years old: Gleason < 6 PSA < 10 > 70 years Gleason < 7 PSA < 15 Triggers for intervention: PSA DT< 3 yr (originally < 2 years) Clinical progression Pathological Upgrade 65% Gleason < 7 & PSA < 10 TORONTO- ACTIVE SURVEILLANCE EXPERIENCE 450 patients, Median age years Median Follow up Inclusion for < 70 years old: Gleason < 6 PSA < 10 > 70 years Gleason < 7 PSA < 15 Triggers for intervention: PSA DT< 3 yr (originally < 2 years) Clinical progression Pathological Upgrade 65% Gleason < 7 & PSA < 10 17
18 TORONTO SERIES- AS DROP OUT RATES 60% of patients Spared radical therapy at 10 years TORONTO OUTCOMES 10 year OS = 68% 10 year CSS = 97.2 % Klotz JCO
19 PSA IS NOT AN ADEQUATE MARKER OF PROGRESSION 305 pt. s offered treatment based on PSA DT, at 5 years, not one pt. developed symptoms or died from prostate Cancer. False trigger for treatment fanged from 42-80% based on PSA DT. Use of PSA triggers (PDA DT<3 yr, PSAv > 2 ng/ml and PSA T>10) would have led to unacceptably high treatment rates Klotz GU ASCO 2011 EPSTEIN very low risk inclusion criteria Median Survival free progression 6.5 years after Diagnosis Median intervention at 2.2 years. 235/ 418 (30.6%) men s biopsies progressed in risk stratification. 106/235 (45.1%) Gleason Score Upgrading 129/ 235 (54.9%) had an increased number of cores Tosian, JCO
20 JOHNS HOPKINS EXPERIENCE WITH SURVEILLANCE BX Of patients on AS, risk factors for eventual therapy included: PSA at diagnosis PSAD at diagnosis Year of cancer diagnosis Tosian et al JCO 2011 PSA Velocity PSA Doubing Time BIOPSY Specimen P=0.06 PSAV on Bx AUC= 0.61 P=0.83 PSA DT on BAUC = 0.57 Radical Prostatectomy PSAV on RP AUC = 0.56 PSADT on RP AUC = 0.51 PSA V or PSADT was not significantly associated with subsequent adverse biopsy findings. Ross et al JCO
21 PCA3 AS A MARKER OF PROGRESSION - Gleason > 7 - Unfavourable, Gleason 6 - Favourable 294 men in the Johns Hopkins AS program provided PCA3. 38 patients had progression on biopsy, 16 had progression in gleason grade 7. PCA 3 could not be used to identify men with progression. Elevated PCA3 > 35 not associated with progression (p=0.15) Tosoain, et al J of Urol 2010 MRI IN MEN WITH UNTREATED LOCALIZED PROSTATE CANCER ON ACTIVE SURVEILLANCE 80 men enrolled in Active surveillance: T1/T2a, PSA < 15 Gleason < 7 <50% positive cores Median age 66 Apparent Diffusion Coeffieint was significant predictor of : Adverse repeat biopsy findings P<0.0001; HR 1.3 (95% CI ), AUC= 0.7 Time to Radical Treatment; P< , HR 1.5 (95% CI ), AUC= 0.7. Eur Urol
22 SUMMARY OF TRIGGERS FOR INTERVENTION PSA, PSA DT or PSA kinetics not adequate to monitor for progression Re-Biopsy is required. PCA 3 has no role so far in monitoring patients on AS protocols. MRI may play a significant role in monitoring tumor progression and guiding surveillance biopsies. OUTCOMES ON AS Primary Outcome- Survival Secondary Outcome- Pathology at time of RP Biochemial Free Recurrence post RP Quality of Life 22
23 Prostate-Cancer Mortality in the RP and WW of the Scandanavian SPCG- 4 vs UofT Active Surveillance Cohort. NEJM Klotz
24 PATHOLOGICAL RESULTS FROM RP IN 6 ACTIVE SURVEILLANCE PROTOCOLS AUA 2012 BIOCHEMICAL FREE SURVIVAL POST DEFINITIVE THERAPY UCSF- 100% at 3 years (n=74) University of Miami- BFS 100% at 3 years (n=12) Johns Hopkins- 96% at 3 years (n=96) ERSPC- 91 % at 3 years (n=81) Toronto- 50% at 5 year (n=130) Cooperberg et al, JCO 2011 Soloway et al, Eur Urol 2010 Tosoian et al, JCO 2011 Van den Bergh et al, Eur Urol 2009 Klotz et al, JCO
25 CLINICAL SIGNIFICANCE OF BIOCHEMICAL RECURRENCE Post Radical Prostatectomy Median 8 years from PSA recurrence to metastatic disease. Median 5 years from metastatic disease to death from prostate cancer. Post Radiation Therapy Median Time to castration resistant prostate cancer is years. 7 year disease specific mortality years 1. PR-7 Data, J Clin Oncol 29: Pound. JAMA 1999, Vol 281, No. 17 SECONDARY CHEMOPREVENTION Retrospective Study on 288 Men on AS for low-risk Disease, Rate of progression significantly lower in dutasteride(18.6 vs. 36.7%). Rate of withdrawal significantly lower (20 vs 37.6%). The absence of 5-ARI was associated with a nearly three fold likelihood of pathologic progression. Follow up to short to comment on survival. 5-ARI initiated in 47 ARI naïve patients, Finelli. Eur. Urol Reclassification occurred in 17% vs. 31% of non-users. Multivariable model showed no-significant risk reduction Ross AE et al, BJUI
26 302 men with Low grade, Low D Amico risk, Gleason < 6 Prostate Cancer N= 155 Placebo N= 147 Dutasteride 0.5mg 10 core Biopsy at initiation, 12 core at 1.5 years and 3 years. 65 Academic Centers Men aged 48-82, life expectancy > 5 years. ct1c-ct2a, Gleason 5-6, PSA < 11 REDEEM- ESTIMATE OF TIME TO PROGRESSION (PATHOLOGICAL OR THERAPEUTIC) Placebo: 70/145 (48%) progressed at 3 years. Dutasteride: 54/144 (38%) progressed at 3 years. HR= 0.62 (95% CI ). Gleason 8 detected in 2 men in Dutasteride group, and 3 men in control on follow up Bx. Dutasteride had more ejaculation disorders. No difference in anxiety levels. Time to progression Placebo Dutasteride 26
27 MORBIDITY OF ACTIVE SURVEILLANCE Repeat biopsies: Increased risk of biopsy related sepsis, 4% risk in 2009 (Fujita, J Urol 2009) Increased risk of erectile dysfunction (Nam RK, J Urol 2010) Anxiety 55% of men are anxious of progression on AS. Increased risk of disease on delayed therapy Lower Urinary Tract Symptoms Glass J Urology, 2012 HOW SATISFIED ARE MEN WITH THEIR TREATMENT? BJU International Volume 107, Issue 11, pages , 17 NOV 2010 DOI: /j X x 27
28 400 men randomised to RP or WW with 281 extra men as population controls. Survey follow up at 3.7 and 13.4 years. 19% in RP group were on ADT, 28% in WW. Physical Symptoms similar, RP had a greater increase in physical symptoms in longitudinal data. ED 84% in RP, 80% in WW HIGH QUALITY OF LIFE IN RP VS WW PATIENTS. Radical Prostatectomy Watchful Waiting R. P. W.W. 4 years 12 years 28
29 OUTCOMES OF ACTIVE SURVEILLANCE Good 10 year data for low risk prostate cancer patients that are observed when compared to radical prostatectomy. (PiVOT) Active Surveillance MAY have improved survival over observation trials There is an incrased risk of high risk pathology and biochemical recurrence at the time of RP. There is minimal, but real, morbidity associated with AS through anxiety, ED and sepsis. HRQOL outcomes between WW and RP groups are both poorer when associated with a healthy population. WW is associated with reduced physical symptoms affecting quality of Life. 29
30 SUMMARY Active Surveillance is a safe option for Very Low Risk Prostate Cancer with no difference in 10 year mortality. There is no proven optimal surveillance Protocol for Active Surveillance. A multifactorial approach weighting patient values, comorbidities and life expectancy must be taken into consideration with measures of prostate cancer risk such as PSA, Biopsy, PCA 3 and MRI to decide risks and benefits of Active surveillance. Clinical trials on risk stratification, tumor markers and imaging in Active Surveillance patients will reveal significant amounts of information on the natural course of low risk prostate cancer. QUESTIONS? 30
31 ACTIVE SURVEILLANCE RISKS Risk of understaging biopsy result No concrete predictor of progression Increased PSA recurrence Increase positive margin rate Anxiety and quality of life still affected BENEFITS Relieves ~ 50% of patients with low risk prostate cancer treatment related morbidity. No reduction in mortality at 10 years Decreased early physical symptoms Another, safe option for patients WHAT WE KNOW ABOUT GOOD RISK PROSTATE CANCER 30% or more of men harbor prostate cancer (Sakr) before age 50 Systematic prostate biopsy results in a 25% prostate cancer detection rate (PCPT) in men with PSA < 3.0 Screening increases the incidence to mortality ratio from 2.5:1 to 15:1 (Schroeder) Need to treat 48 men in screened population to prevent one prostate cancer death Mortality rates have fallen in both screened and unscreened populations (Lu-Yao; Albertsen) 31
32 ???? WHERE IS THIS FROM PROBABILITY OF BEING PROGRESSION FREE 96% at 1 year 79% at 2 years 65% at 5 years J Urol 2004 Inclusion Criteria (EPSTEIN): T1c disease, PSAD < 0.15 ng/ml, Gleason score <6, <2 biopsy cores with cancer maximum of 50% core involvement Surveillance protocol includes: PSA and DRE q 6 mo. Annual 12- to 14-core surveillance biopsy (recently routine transition zone biopsies) Curative therapy was recommended based on Disease reclassification from upgrade to Gleason score >6, two cores with cancer, >50% cancer involvement of any core NOT PSA concentration or kinetics Tosian, Trock, Lansi, Feng, Epstein, Partin, Walsh, Carter JCO
33 UCSF- CANCER OF THE PROSTATE RISK ASSESSMENT SCORE (CAPRA) 33
Sommerakademie Munich, June
Active surveillance: Shrinking the grey zone Sommerakademie Munich, June 30 2016 Active surveillance Overview of 20 year history Laurence Klotz, MD, CM Professor of Surgery Sunnybrook Heatlh Sciences Centre
More informationSorveglianza Attiva update
Sorveglianza Attiva update Dr. Sergio Villa Dr. Riccardo Valdagni www.thelancet.com Published online August 7, 2014 http://dx.doi.org/10.1016/s0140-6736(14)60525-0 the main weakness of screening is a high
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationPre-test. Prostate Cancer The Good News: Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest
Pre-test Matthew R. Cooperberg, MD, MPH UCSF 40 th Annual Advances in Internal Medicine Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest 1. I do not offer routine PSA screening, and
More informationProstate Cancer Incidence
Prostate Cancer: Prevention, Screening and Treatment Philip Kantoff MD Dana-Farber Cancer Institute Professor of fmedicine i Harvard Medical School Prostate Cancer Incidence # of patients 350,000 New Cases
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationConceptual basis for active surveillance
Conceptual basis for active surveillance 1. Screening results in overdiagnosis 2. Clinically insignificant disease can be identified 3. All treatments have significant side effects and cost. 4. Delayed
More informationACTIVE SURVEILLANCE OR WATCHFUL WAITING
Prostate Cancer ACTIVE SURVEILLANCE OR WATCHFUL WAITING María Teresa Bourlon, MD MS Head, Urologic Oncology Clinic Hemato-Oncology Department Instituto Nacional de Ciencias Médicas y Nutrición Salvador
More informationRisk Migration ( ct2c=high)
Risk Migration ( ctc=high) Prostate Cancer Over- Detection, but Selective Treatment Active Surveillance Peter R. Carroll, MD, MPH Department of Urology University of California, San Francisco February,
More informationPROSTATE CANCER SURVEILLANCE
PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
More informationTo be covered. Screening, early diagnosis, and treatment including Active Surveillance for prostate cancer: where is Europe heading for?
To be covered Screening, early diagnosis, and treatment including Active Surveillance for prostate cancer: where is Europe heading for? Europa Uomo meeting Stockholm 29 Chris H.Bangma Rotterdam, The Netherlands
More informationProstate Biopsy. Prostate Biopsy. We canʼt go backwards: Screening has helped!
We canʼt go backwards: Screening has helped! Robert E. Donohue M.D. Denver V.A. Medical Center University of Colorado Prostate Biopsy Is cure necessary; when it is possible? Is cure possible; when it is
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationClinical Case Conference
Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationProstate Cancer Who needs active surveillance?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller Prostate Cancer Who needs active surveillance? Klinische und molekulare Charakterisierung des Hoch-Risiko-Prostatakarzinoms.
More informationPublished Ahead of Print on April 4, 2011 as /JCO J Clin Oncol by American Society of Clinical Oncology INTRODUCTION
Published Ahead of Print on April 4, 2011 as 10.1200/JCO.2010.32.8112 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2010.32.8112 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E
More informationScreening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality
Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality Sanoj Punnen, MD, MAS Assistant Professor of Urologic Oncology University of Miami, Miller School of Medicine and Sylvester
More informationActive surveillance: Shrinking the grey zone. Sommerakademi e Munich, June rd FOIUS Tel Aviv, July 2016
Active surveillance: Shrinking the grey zone Active surveillance: 3 rd FOIUS Tel Aviv, July 2016 Shrinking the grey zone Sommerakademi e Munich, June 30 2016 Active Surveillance for low risk PCa What has
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationWhere are we with PSA screening?
Where are we with PSA screening? Faculty/Presenter Disclosure Rela%onships with commercial interests: None Disclosure of Commercial Support This program has received no financial support. This program
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationProstate Cancer: from Beginning to End
Prostate Cancer: from Beginning to End Matthew D. Katz, M.D. Assistant Professor Urologic Oncology Robotic and Laparoscopic Surgery University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer
More informationEarly outcomes of active surveillance for localized prostate cancer
Original Article ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER HARDIE et al. Early outcomes of active surveillance for localized prostate cancer CLAIRE HARDIE, CHRIS PARKER, ANDREW NORMAN*, ROS EELES,
More informationBPH with persistently elevated PSA 아주대학교김선일
BPH with persistently elevated PSA 아주대학교김선일 PSA in BPH: present status AUA & EAU BPH guideline: PSA: recommended test AUA practice guideline committee. J Urol 2003;170:530 Madersbacher. Eur Urol 2004;46:547
More informationAdam Raben M.D. Helen F Graham Cancer Center
Adam Raben M.D. Helen F Graham Cancer Center Is the biopsy sample representative of the extent of the disease in your patient with clinically low-risk prostate cancer? BIOPSY RP registry (n=8095) 3+3=6
More informationFellow GU Lecture Series, Prostate Cancer. Asit Paul, MD, PhD 02/20/2018
Fellow GU Lecture Series, 2018 Prostate Cancer Asit Paul, MD, PhD 02/20/2018 Disease Burden Screening Risk assessment Treatment Global Burden of Prostate Cancer Prostate cancer ranked 13 th among cancer
More informationProstate Cancer Screening: Risks and Benefits across the Ages
Prostate Cancer Screening: Risks and Benefits across the Ages 7 th Annual Symposium on Men s Health Continuing Progress: New Gains, New Challenges June 10, 2009 Michael J. Barry, MD General Medicine Unit
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More information10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION
THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION Lenette Walters, MS, MT(ASCP) Medical Affairs Manager Beckman Coulter, Inc. *phi is a calculation using the values from PSA, fpsa and p2psa
More informationActive Surveillance for Intermediate Risk Prostate Cancer
Active Surveillance for Intermediate Risk Prostate Cancer Eric Wallen, M.D., FACS Professor Department of Urology The University of North Carolina at Chapel Hill Disclosures: None Objectives Understand
More informationPCa Commentary. Executive Summary: The "PCa risk increased directly with increasing phi values."
1101 Madison Street Suite 1101 Seattle, WA 98104 P 206-215-2490 www.seattleprostate.com PCa Commentary Volume 77 September October 2012 CONTENT Page The Prostate 1 Health Index Active Surveillance 2 A
More informationHealth Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015
Health Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015 Outline Epidemiology of prostate cancer Purpose of screening Method of screening Contemporary screening trials
More informationWhen radical prostatectomy is not enough: The evolving role of postoperative
When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer
More informationNewer Aspects of Prostate Cancer Underwriting
Newer Aspects of Prostate Cancer Underwriting Presented By: Jack Swanson, M.D. Keith Hoffman, NFP Moments Made Possible Objectives To review and discuss Conflicting messages about PSA testing Cautions
More informationPROSTATE CANCER Amit Gupta MD MPH
PROSTATE CANCER Amit Gupta MD MPH Depts. of Urology and Epidemiology Amit-Gupta-1@uiowa.edu dramitgupta@gmail.com Tel: 319-384-5251 OUTLINE PSA screening controversy How to use PSA more effectively Treatment
More informationPaul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia
Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia Virginia - Chesapeake Bay Landfall: Virginia Beach, April 29 th, 1607 PSA Failure after Radical Prostatectomy
More informationLocal Recommendations for Active Surveillance of Prostate Cancer
February 15 Local Recommendations for Active Surveillance of Prostate Cancer Chris Dawson Urology Lead Clinician February 2015 www.pchurology.co.uk Summary and Recommendations 1. There is no single set
More informationMr Jeremy Grummet, Urological Surgeon MBBS, MS, FRACS Foundation 49 Men s Health Symposium August 2015
www.drjeremygrummet.com.au www.aua.com.au Mr Jeremy Grummet, Urological Surgeon MBBS, MS, FRACS Foundation 49 Men s Health Symposium August 2015 The dilemma Most men die with prostate cancer rather than
More informationProstate Cancer Genomics When To Treat and With What? Ashley E. Ross, M.D., Ph.D. Texas Urology Specialists August 2017
Prostate Cancer Genomics When To Treat and With What? Ashley E. Ross, M.D., Ph.D. Texas Urology Specialists August 2017 Relevant Disclosures Advisory role, ownership interest, previous unrestricted grant
More informationUrological Society of Australia and New Zealand PSA Testing Policy 2009
Executive summary Urological Society of Australia and New Zealand PSA Testing Policy 2009 1. Prostate cancer is a major health problem and is the second leading cause of male cancer deaths in Australia
More informationMR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
More informationProstate Cancer Active Surveillance: Rationale, Outcomes and Future Directions
Prostate Cancer Active Surveillance: Rationale, Outcomes and Future Directions Daniel W. Lin, MD Professor and Chief of Urologic Oncology Bridges Endowed Professorship of Prostate Cancer Research Department
More informationProstate MRI: Who needs it?
Prostate MRI: Who needs it? Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Abdominal Imaging Magnetic Resonance Science Center
More informationProstate MRI for local staging and surgical planning in prostate cancer
Prostate MRI for local staging and surgical planning in prostate cancer 15th Annual Floyd A. Fried Advances in Urology Symposium June 23, 2017 Ray Tan, MD, MSHPM Assistant Professor Disclosures None Objectives
More informationStephen McManus, MD David Levi, MD
Stephen McManus, MD David Levi, MD Prostate MRI Indications INITIAL DETECTION, STAGING, RECURRENT TUMOR LOCALIZATION, RADIATION THERAPY PLANNING INITIAL DETECTION Clinically suspected prostate cancer before
More informationLong-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer
Published Ahead of Print on December 15, 1 as 1.1/JCO.1.55.119 The latest version is at http://jco.ascopubs.org/cgi/doi/1.1/jco.1.55.119 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Long-Term
More informationDebate: Whole pelvic RT for high risk prostate cancer??
Debate: Whole pelvic RT for high risk prostate cancer?? WPRT well, at least it ll get the job done.or will it? Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Using T-stage,
More informationUnderstanding the Performance of Active Surveillance Selection Criteria in Diverse Urology Practices
Understanding the Performance of Active Surveillance Selection Criteria in Diverse Urology Practices Scott R. Hawken,* Paul R. Womble,* Lindsey A. Herrel, Zaojun Ye, Susan M. Linsell, Patrick M. Hurley,
More informationPSA testing in New Zealand general practice
PSA testing in New Zealand general practice Ross Lawrenson, Charis Brown, Fraser Hodgson. On behalf of the Midland Prostate Cancer Study Group Academic Steering Goup: Zuzana Obertova, Helen Conaglen, John
More informationDong Hoon Lee, Kyo Chul Koo, Seung Hwan Lee, Koon Ho Rha, Young Deuk Choi, Sung Joon Hong and Byung Ha Chung
Jpn J Clin Oncol 2013;43(5)553 558 doi:10.1093/jjco/hyt041 Advance Access Publication 11 April 2013 Low-risk Prostate Cancer Patients Without Visible Tumor (T1c) On Multiparametric MRI Could Qualify for
More informationProstate Cancer- Screening and Selected Treatment Dilemmas COPYRIGHT. Marc B. Garnick MD. Update in Internal Medicine.
Prostate Cancer- Screening and Selected Treatment Dilemmas Marc B. Garnick MD Update in Internal Medicine 4 December 2016 Financial Disclosures Marc B. Garnick MD, FACP Gorman Brothers Clinical Professor
More informationDong Hoon Lee, Ha Bum Jung, Seung Hwan Lee, Koon Ho Rha, Young Deuk Choi, Sung Jun Hong, Seung Choul Yang and Byung Ha Chung *
Jpn J Clin Oncol 2012;42(11)1079 1085 doi:10.1093/jjco/hys147 Advance Access Publication 17 September 2012 Comparison of Pathological Outcomes of Active Surveillance Candidates Who Underwent Radical Prostatectomy
More informationPSA and the Future. Axel Heidenreich, Department of Urology
PSA and the Future Axel Heidenreich, Department of Urology PSA and Prostate Cancer EAU Guideline 2011 PSA is a continuous variable PSA value (ng/ml) risk of PCa, % 0 0.5 6.6 0.6 1 10.1 1.1 2 17.0 2.1 3
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationActive surveillance: From Biology to Bedside. Who is Going to Fail? Active surveillance: Shrinking the grey zone. Sommerakademi e Munich, June
Active surveillance: From Biology to Bedside Who is Going to Fail? Active surveillance: Shrinking the grey zone Sommerakademi e Munich, June 30 2016 What is the main reason low risk patients fail? 1. GG1/Gleason
More informationTrends in Prostate Cancer Bob Weir AVP Underwriting Research Canada Life Reinsurance
Trends in Prostate Cancer Bob Weir AVP Underwriting Research Canada Life Reinsurance Metropolitan Underwriting Discussion Group Annual Meeting January 30, 2017 Prostate Cancer is Common Rudy Giuliani Dx
More informationContemporary Approaches to Screening for Prostate Cancer
Contemporary Approaches to Screening for Prostate Cancer Gerald L. Andriole, MD Robert K. Royce Distinguished Professor Chief of Urologic Surgery Siteman Cancer Center Washington University School of Medicine
More informationDisclosures. Prostate and Bladder Cancer: Jonathan E. Rosenberg, M.D. U.S. Cancer Statistics: Prostate Cancer Known Risk Factors
Prostate and Bladder Cancer: 2012 Jonathan E. Rosenberg, M.D. Associate Attending Section Head, Non-Prostate Genitourinary Oncology Service Memorial Sloan-Kettering Cancer Center Disclosures Consulting
More informationExpanded criteria for active surveillance in prostate cancer: a review of the current data
Review Article Expanded criteria for active surveillance in prostate cancer: a review of the current data Cameron Jones 1, Mina M. Fam 2, Benjamin J. Davies 2 1 University of Pittsburgh School of Medicine,
More informationThe Role of Adjuvant vs Salvage Radiation Therapy after Prostatectomy. Dr. Matt Andrews Supervisor: Dr. David Bowes
The Role of Adjuvant vs Salvage Radiation Therapy after Prostatectomy Dr. Matt Andrews Supervisor: Dr. David Bowes Objectives Discuss the evidence for adjuvant radiotherapy (ART) EORTC, SWOG, ARO Current
More informationUntreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes
Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes A. A. Hussein,* C. J. Welty,* N. Ameli,* J. E. Cowan, M. Leapman,*
More informationState-of-the-art: vision on the future. Urology
State-of-the-art: vision on the future Urology Francesco Montorsi MD FRCS Professor and Chairman Department of Urology San Raffaele Hospital Vita-Salute San Raffaele University Milan, Italy Disclosures
More informationEarly Experience With Active Surveillance in Low-Risk Prostate Cancer Treated
www.kjurology.org http://dx.doi.org/.4/kju.4...67 Original Article Urological Oncology http://crossmark.crossref.org/dialog/?doi=.4/kju.4...67&domain=pdf&date_stamp=47 Early Experience With Active Surveillance
More informationHelping you make better-informed decisions 1-5
Helping you make better-informed decisions 1-5 The only test that provides an accurate assessment of prostate cancer aggressiveness A prognostic medicine product for prostate cancer. A common diagnosis
More informationMr Declan Cahill Consultant Urological Surgeon The Royal Marsden
Diagnosing prostate cancer Mr Declan Cahill Consultant Urological Surgeon 2 Marsden GP Education Day 22 February 2016 Should I have a PSA test? Can I have a PSA test? prostatecanceruk.org 4 83% raised
More informationLow risk. Objectives. Case-based question 1. Evidence-based utilization of imaging in prostate cancer
Evidence-based utilization of imaging in prostate cancer Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Objectives State the modalities,
More informationHormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice
european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio
More informationRadical Prostatectomy:
Overtreatment and undertreatment Radical Prostatectomy: An Emerging Standard of Care for High Risk Prostate Cancer Matthew R. Cooperberg, MD,MPH UCSF Radiation Oncology Update San Francisco, CA April 2,
More informationPCa Commentary. Volume 79 May June 2014
1221 Madison Street, 1 st Floor Seattle, WA 98104 P 206-215-2480 www.seattleprostate.com PCa Commentary Volume 79 May June 2014 CONTENT: Active Surveillance Page 1 Firmagon and Lupron Page 5 ACTIVE SURVEILLANCE:
More informationVALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE. ELENA CASTRO Spanish National Cancer Research Centre
VALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 17-18 October 2017 Prostate Specific Antigen (PSA) has a role in:
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationExternal validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer
External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer Mathieu Roumiguié, Jean-Baptiste Beauval, Thomas Filleron*,
More informationestimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c.
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTION OF AGGRESSIVE RECURRENCE AFTER RP SCHROECK et al. BJUI BJU INTERNATIONAL Do nomograms predict aggressive recurrence after radical
More informationPCA MORTALITY VS TREATMENTS
PCA MORTALITY VS TREATMENTS Terrence P McGarty White Paper No 145 July, 2017 In a recent NEJM paper the authors argue that there is no material difference between a prostatectomy and just "observation"
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationPercent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer
Review Article Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer Meenal Sharma 1, Hiroshi Miyamoto 1,2,3 1 Department of Pathology and Laboratory
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #104 (NQF 0390): Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS
More informationHow do I control (monitor) patients receiving TRT after prostate cancer treatment
How do I control (monitor) patients receiving TRT after prostate cancer treatment Anthony J. Bella MD, FRCSC Greta and John Hansen Chair in Men s Health Research Division of Urology, Department of Surgery
More informationGUIDELINEs ON PROSTATE CANCER
GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent
More informationUtility of Prostate MRI. John R. Leyendecker, MD
Utility of Prostate MRI John R. Leyendecker, MD Professor of Radiology and Urology Executive Vice Chair of Clinical Operations Section Head, Abdominal Imaging Wake Forest University School of Medicine;
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationProstate Cancer Update 2017
Prostate Cancer Update 2017 Arthur L. Burnett, MD, MBA, FACS Patrick C. Walsh Distinguished Professor of Urology The James Buchanan Brady Urological Institute The Johns Hopkins Medical Institutions Baltimore,
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationTiming of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
More informationProstate Biopsy Protocol in Active Surveillance for Prostate Cancer Causes ED. Con Man: Andrew McCullough May
Prostate Biopsy Protocol in Active Surveillance for Prostate Cancer Causes ED Con Man: Andrew McCullough May 12 2017 It may be particularly useful as an initial screening instrument in a general practice
More informationTo treat or not to treat: When to treat! A case presentation
To treat or not to treat: When to treat! A case presentation Filip Ameye, MD,Phd Universitary Hospitals Leuven, Belgium Departement of Urology Prostate Center A case presentation Pt. 76 y. Mild LUTS (07/1999)
More informationClinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline Very Low-/Low-Risk Disease
Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline Very Low-/Low-Risk Disease Jeffrey A. Cadeddu, MD Professor, Department of Urology UT Southwestern Medical Center Vice-Chair, AUA/ASTRO/SUO
More informationFactors Associated with Initial Treatment for Clinically Localized Prostate Cancer
Factors Associated with Initial Treatment for Clinically Localized Prostate Cancer Preliminary Results from the National Program of Cancer Registries Patterns of Care Study (PoC1) NAACCR Annual Meeting
More informationObjectives. Prostate Cancer Screening and Surgical Management
Prostate Cancer Screening and Surgical Management Dr. Ken Jacobsohn Director, Minimally Invasive Urologic Surgery Assistant Professor, Department of Urology Medical College of Wisconsin Objectives Update
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationPCa Commentary. Seattle Prostate Institute CONTENTS. Volume 71 September-October 2011
Volume 71 September-October 2011 PCa Commentary CONTENTS PERMANENT SEED BRACHYTHERAPY FOR HIGH- RISK PROSTATE CANCER: 1 CABOZANTINIB: Startling Responses Reported at June ASCO Meeting in Metastatic Castrate
More informationPredictive role of free prostate specific antigen in a prospective active surveillance program (PRIAS)
World J Urol (2015) 33:1735 1740 DOI 10.1007/s00345-015-1542-3 ORIGINAL ARTICLE Predictive role of free prostate specific antigen in a prospective active surveillance program (PRIAS) Hanna Vasarainen 1
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More information